These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 21947680)

  • 21. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
    Cinieri S; Chan A; Altundag K; Vandebroek A; Tubiana-Mathieu N; Barnadas A; Dodyk P; Lazzarelli S; Botha M; Rauch D; Villanova G; Coskun U
    Clin Breast Cancer; 2017 Apr; 17(2):91-99.e1. PubMed ID: 27756583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer.
    Babacan T; Efe O; Hasirci AS; Demirci F; Buyukhatipoglu H; Balakan O; Sarici F; Kertmen N; Esin E; Akin S; Ates O; Aksoy S; Sever AR; Altundag K
    Tumori; 2015; 101(4):418-23. PubMed ID: 25953439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A comparative randomized phase-II study of Xeloda (capecitabine) and paclitaxel in patients with breast cancer progressing after anthracycline antibiotics].
    Moiseenko VM; O'Reilly SM; Dalbot DC; Van Belle S; Gordon RJ; Griffin T; Osterwalder B
    Vopr Onkol; 2000; 46(3):285-9. PubMed ID: 10976273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Moving forward with capecitabine: a glimpse of the future.
    Biganzoli L; Martin M; Twelves C
    Oncologist; 2002; 7 Suppl 6():29-35. PubMed ID: 12454317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.
    Blum JL; Dieras V; Lo Russo PM; Horton J; Rutman O; Buzdar A; Osterwalder B
    Cancer; 2001 Oct; 92(7):1759-68. PubMed ID: 11745247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.
    Blum JL; Jones SE; Buzdar AU; LoRusso PM; Kuter I; Vogel C; Osterwalder B; Burger HU; Brown CS; Griffin T
    J Clin Oncol; 1999 Feb; 17(2):485-93. PubMed ID: 10080589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer.
    Ambros T; Zeichner SB; Zaravinos J; Montero AJ; Ahn E; Aruna M; Kronish L; Mahtani RL; Vogel CL
    Breast Cancer Res Treat; 2014 Jul; 146(1):7-14. PubMed ID: 24899084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma.
    Bajetta E; Di Bartolomeo M; Mariani L; Cassata A; Artale S; Frustaci S; Pinotti G; Bonetti A; Carreca I; Biasco G; Bonaglia L; Marini G; Iannelli A; Cortinovis D; Ferrario E; Beretta E; Lambiase A; Buzzoni R;
    Cancer; 2004 Jan; 100(2):279-87. PubMed ID: 14716761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer.
    Murad AM
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):26-32. PubMed ID: 14768402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer.
    Wagstaff AJ; Ibbotson T; Goa KL
    Drugs; 2003; 63(2):217-36. PubMed ID: 12515569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme.
    Schott AF; Rae JM; Griffith KA; Hayes DF; Sterns V; Baker LH
    Cancer Chemother Pharmacol; 2006 Jul; 58(1):129-35. PubMed ID: 16283312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG.
    Smorenburg CH; de Groot SM; van Leeuwen-Stok AE; Hamaker ME; Wymenga AN; de Graaf H; de Jongh FE; Braun JJ; Los M; Maartense E; van Tinteren H; Nortier JWR; Seynaeve C
    Ann Oncol; 2014 Mar; 25(3):599-605. PubMed ID: 24504445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
    Kara IO; Sahin B; Erkisi M
    Breast; 2006 Jun; 15(3):414-24. PubMed ID: 16188440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral 5-FU analogues in the treatment of breast cancer.
    Bunnell CA; Winer EP
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):39-43. PubMed ID: 9830624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical experience of capecitabine in metastatic breast cancer.
    O'Shaughnessy J
    Eur J Cancer; 2002 Feb; 38 Suppl 2():10-4. PubMed ID: 11841930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
    Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
    J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Xeloda and Taxotere: a review of the development of the combination for use in metastatic breast cancer.
    McDonald F; Miles D
    Int J Clin Pract; 2003; 57(6):530-4. PubMed ID: 12918893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination versus sequential single-agent therapy in metastatic breast cancer.
    Miles D; von Minckwitz G; Seidman AD
    Oncologist; 2002; 7 Suppl 6():13-9. PubMed ID: 12454315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer.
    Batista N; Perez-Manga G; Constenla M; Ruiz A; Carabantes F; Castellanos J; Gonzalez Barón M; Villman K; Söderberg M; Ahlgren J; Casinello J; Regueiro P; Murias A
    Br J Cancer; 2004 May; 90(9):1740-6. PubMed ID: 15150624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature.
    Hennessy BT; Gauthier AM; Michaud LB; Hortobagyi G; Valero V
    Ann Oncol; 2005 Aug; 16(8):1289-96. PubMed ID: 15890665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.